Thiotepa
Disease Related To Hematopoietic Stem Cell Transplant
Explore 55 assets in Disease Related To Hematopoietic Stem Cell Transplant →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
medac GmbH
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05534620CT.gov Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | — | Completed | — | — | — |
NCT04678401CT.gov IS-free Treg HaploHCT | — | Recruiting | — | — | — |
NCT03779854CT.gov Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | — | Recruiting | — | — | — |
NCT02653196CT.gov A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | — | Terminated | — | — | — |
NCT02220985CT.gov Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | — | Completed | — | — | — |
NCT01010217CT.gov Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | — | Completed | — | — | — |
NCT00972101CT.gov Infusion of Expanded Cord Blood T Cells | — | Withdrawn | — | — | — |
NCT00857389CT.gov Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Hematopoietic Stem Cell Transplant
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thiotepa (this asset) | medac GmbH | P2 | BB · 70 |
| Busulfanum | Institute of Hematology & Blood Diseases Hospital, China | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Nivestim | National Cancer Institute (NCI) | P2/3 | BBB |
| Decitabine | Chinese PLA General Hospital | P4 | BBB |
| Rituximab | M.D. Anderson Cancer Center | P2 | BBB |
| Tacrolimus | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | P3 | BB |
| Cyclosporin A | The First Affiliated Hospital of Soochow University | P4 | BB |
| Cytarabine | The First Affiliated Hospital of Soochow University | P3 | BB |
+42 more in the Disease Related To Hematopoietic Stem Cell Transplant cohort
Other indications for Thiotepa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Graft Versus Host Disease | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 72 |
| Juvenile Myelomonocytic Leukemia | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Thiotepa in Disease Related To Hematopoietic Stem Cell Transplant. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thiotepa-disease-related-to-hematopoietic-stem-cell-transplant
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →